MOTS-c
Also known as Mitochondrial ORF of the 12S rRNA type-c, Mitochondrial-derived peptide MOTS-c, CB4211 (analog)
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA that acts as a metabolic signal, improving insulin sensitivity and exercise capacity in mice. People use it for fat loss, endurance, and metabolic aging.
Reviewed by the amino101 editorial team. , first published .
Quick start
What people commonly do. Not a prescription.- Typical dose
- 5 to 10 mg
- How often
- two to three times per week
- Where
- Subcutaneous, abdomen or thigh; intramuscular is also used
- Timing
- morning or before exercise, often fasted
- Effects timeline
- energy and workout endurance reports over 2 to 4 weeks, body composition changes at 6 to 8 weeks if they happen at all
- Storage
- fridge 2 to 8 C once mixed, use within 4 weeks
- Cycle length
- 4 to 8 weeks
- Break between
- 4 weeks, then reassess
Overview
MOTS-c was identified in 2015 by Changhan Lee and Pinchas Cohen at the University of Southern California. It is encoded in a short open reading frame inside the mitochondrial 12S ribosomal RNA gene, which was assumed for decades to make only RNA. That makes it one of a small family of mitochondrial-derived peptides, alongside humanin and the SHLPs, and it reframed mitochondria as organelles that send out their own hormone-like signals.
The mouse data are what drive interest. MOTS-c injections prevented diet-induced obesity and insulin resistance, improved glucose handling in aged mice, and, in a 2021 study, restored exercise capacity in old mice to the point where treated animals doubled their running time. Levels in muscle and blood rise with exercise in humans and decline with age. A natural variant of the MOTS-c sequence found in East Asian populations is linked to higher type 2 diabetes risk, which is indirect human evidence that the peptide matters metabolically.
Direct human treatment data are limited. CohBar developed a modified analog, CB4211, which completed a phase 1a/1b study in people with obesity and fatty liver, showing acceptable safety and modest changes in glucose and body weight, before the company changed direction. Native MOTS-c has not been through a proper human trial. The community treats it as an exercise mimetic and metabolic aid, usually injected a few times per week.
How it works
MOTS-c works largely through the folate and methionine cycles. It inhibits an enzyme in the folate cycle, which lowers purine synthesis and raises AICAR, an endogenous activator of AMPK. AMPK activation increases glucose uptake in skeletal muscle, boosts fatty acid oxidation, and improves mitochondrial biogenesis, which together resemble the effects of exercise. Under metabolic stress MOTS-c also moves from the cytoplasm into the nucleus, where it binds stress-response transcription factors including NRF2 and adjusts expression of antioxidant and metabolic genes. It acts on muscle preferentially, with smaller effects on liver and fat. Its rise with exercise and decline with age suggest it is a normal part of how mitochondria communicate their energy status to the rest of the body.
Where the research stands
Insulin sensitivity and metabolic healthModerate evidence
- Diet-induced insulin resistance. Mouse studies, prevented obesity and insulin resistance on a high-fat diet and improved insulin sensitivity in aged mice.
- Type 2 diabetes risk. Human genetic association, a natural MOTS-c variant in East Asian populations tracks with higher diabetes risk.
Exercise capacityModerate evidence
- Endurance in aged animals. Mouse study, treatment roughly doubled running capacity in old mice.
- Exercise as a natural trigger. Human pilot data, exercise raised MOTS-c levels in muscle and plasma.
Fatty liver and obesityEmerging
- Obesity with fatty liver (CB4211 analog). Phase 1 human study of the analog showed acceptable safety and modest metabolic signals, not native MOTS-c.
Aging and longevityEmerging
- Healthspan in aged mice. Rodent studies on physical performance and metabolic markers in old animals; no human aging data.
- rodentMOTS-c prevented high-fat-diet obesity and insulin resistance in mice and improved insulin sensitivity in aged mice.
- rodentMOTS-c treatment roughly doubled running capacity in old mice and improved physical performance in young mice on a high-fat diet.
- in vitroMOTS-c translocates to the nucleus during metabolic stress and regulates stress-response gene expression.
- human pilotExercise raised MOTS-c levels in human skeletal muscle and plasma.
- human pilotThe CB4211 analog completed a phase 1 study in obesity and fatty liver with acceptable safety and modest metabolic signals.
- human pilotA natural MOTS-c sequence variant in East Asian populations is associated with increased type 2 diabetes risk.
Rodent and in vitro mean no human data for that finding. Human pilot means small, often uncontrolled. Human RCT means randomized and controlled. Clinical means an approved drug with regulatory data.
Levels over time
Modeled from the half-life. Illustrative, not measured.A half-life of 30 min against dosing every 2.3 d means each dose has cleared before the next. Nothing stacks; you start from zero every time, and the tissue effect is what carries over.
Plasma clearance is fast, but the AMPK signaling and gene expression changes it triggers in muscle last much longer, which is why community protocols dose two or three times a week rather than daily.
MOTS-c dosage and protocols
Community protocols run 4 to 8 weeks at two or three injections a week, then stop for a month. Some people front-load with three doses a week for the first two weeks and drop to two. There is no evidence for any particular schedule; the mouse work used daily injections at doses far above what people use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Conservative start | 5 mg | twice weekly | Subcutaneous |
| Common community protocol | 10 mg | twice weekly | Subcutaneous |
| Loading phase (community) | 10 mg | three times weekly | Subcutaneous |
| Training day only | 5 to 10 mg | on training days, up to three per week | Subcutaneous or intramuscular, 30 to 60 minutes before |
Morning or pre-workout dosing is the norm, often fasted, on the theory that it works through the same AMPK pathway exercise activates. Anyone on glucose-lowering drugs should eat around the injection, since transient glucose dips are reported. It is usually paired with SS-31 on the same schedule in mitochondrial stacks.
Community protocols range widely. Mouse studies used 5 to 15 mg per kg, which scales to much larger human doses than anyone uses, so the human-equivalent dose is unknown.
Dose calculator
U-100 insulin syringeUnits are a volume on the syringe, not an amount of peptide. Concentration changes every time you change the water volume. The standalone calculator explains the math.
| Vial | Suggested water | Concentration | Low dose draw |
|---|---|---|---|
| 10 mg | 1 mL | 10 mg/mL | 50 units |
| 20 mg | 2 mL | 10 mg/mL | 50 units |
| 40 mg | 4 mL | 10 mg/mL | 50 units |
How to reconstitute MOTS-c
- 1
Wash your hands and wipe the work surface. Swab both vial stoppers with alcohol and let them dry.
- 2
Pick the water volume with the calculator above and write it on the vial. The concentration means nothing without it.
- 3
Draw the bacteriostatic water into a mixing syringe.
- 4
Insert at an angle and let the water run down the inside wall. Never squirt it straight onto the powder.
- 5
Swirl gently or leave it to dissolve. Do not shake.
- 6
Label with the date and water volume. Store in the fridge at 2 to 8 C and use within about 4 weeks.
- 7
Unmixed vials keep for months in the fridge and longer in the freezer, sealed and out of light.
- Full walkthrough with syringe reading and site rotation: reconstitution guide.
- ✓White, fluffy cake
Lyophilized powder should look like a small white puck or fluffy cake at the bottom of the vial. That is a proper freeze-dry.
- ✓Clear after mixing
Once dissolved the solution should be water-clear with nothing floating in it.
- !Slight clumping
Small clumps that dissolve with gentle swirling are fine. Shipping compacts powder.
- ✕Collapsed or melted
Powder stuck to the sides, glassy, or shrunken means it got hot in transit. Contact the vendor.
- ✕Cloudy or particles
Persistent cloudiness or visible particles after mixing means degraded or contaminated product. Do not use it.
- Week 1 to 2
Injection site redness, possibly a short spell of fatigue or flushing after dosing, occasional glucose dips. Some people report better energy right away, which may be placebo.
- Week 2 to 4
Reports of easier cardio and better recovery are the most common claim; nothing on the scale yet.
- Week 4 to 8
Modest body composition changes if any, mostly in people who are also training and dieting. Many people notice nothing measurable.
Interactions and stacking
SS-31synergistic
SS-31 protects the mitochondrial membrane while MOTS-c drives metabolic signaling; complementary mechanisms, no combined data.
NAD+compatible
NAD+ supports the same mitochondrial energy pathways MOTS-c signals through; a common pairing with no data.
Semaglutidecompatible
Used during GLP-1 fat loss to support exercise capacity and muscle; no combined data.
SLU-PP-332compatible
Both marketed as exercise mimetics with overlapping pathways; stacking two untested compounds muddies any result.
Insulin and other glucose-lowering drugscaution
MOTS-c improves glucose uptake in muscle and people report transient dips, so hypoglycemia risk rises with these drugs.
Metformincaution
Both act through AMPK, so the glucose-lowering effects may add; watch readings rather than assume it is fine.
SS-31 protects mitochondrial membranes while MOTS-c drives metabolic signaling, so people pair them for a mitochondrial stack.
Some people add MOTS-c during GLP-1 fat loss hoping to preserve muscle and exercise capacity, though there is no combined data.
NAD+ supports the same mitochondrial energy pathways that MOTS-c signals through.
Safety
- ▲Injection site redness, itching or small lumps
- ▲Transient fatigue or flushing after a dose
- ▲Temporary drops in blood glucose
- ▲Headache
- ▲Mild nausea
- ▲No human trial of native MOTS-c exists; only the analog CB4211 has phase 1 data.
- ▲Injection site reactions and transient fatigue or flushing are the most common reports.
- ▲Some people note temporary drops in blood glucose; people on glucose-lowering drugs should watch for that.
- ▲Mouse effective doses per kilogram are far above community doses, so the human-effective range is a guess.
- ▲Marketed as an exercise pill; it is not a substitute for actually training.
- ■Shakiness, sweating or confusion that points to low blood sugar, especially on glucose-lowering drugs
- ■Injection site reactions that spread or do not settle within a few days
- ■No measurable change after 8 weeks
- ■You compete in tested sport; unapproved peptides fall under the WADA catch-all rule
Community poll
Self-reported by visitors. Not clinical evidence.MOTS-c: frequently asked
Is MOTS-c an exercise mimetic?
In mice, treatment reproduced several effects of exercise, including AMPK activation in muscle and improved endurance. Levels also rise naturally with exercise in humans. Whether an injected dose gives a person any meaningful fraction of what training does has not been tested.
Will it help me lose weight?
It prevented fat gain in mice on a high-fat diet and the CB4211 analog produced modest weight changes in a small phase 1 study. That is a long way from a fat loss drug. Expect small effects at most, and only alongside diet and exercise.
How is it different from humanin?
Both are mitochondrial-derived peptides, but humanin comes from the 16S rRNA gene and leans toward neuroprotection and cell survival, while MOTS-c comes from the 12S rRNA gene and is mainly a metabolic regulator acting on muscle.
How often do people inject it?
Two or three times per week at 5 to 10 mg is the most commonly cited protocol. Some use it daily at lower doses or only around training sessions. None of these schedules have human data behind them.
References
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015
- MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2021
- The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metabolism, 2018
- A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide MOTS-c. Aging, 2021